SLRX
Salarius Pharmaceuticals Inc
-8.52%
$2.23 - $2.04
Feb 8th 2023 - Mar 22nd 2023
Oct, 28, 2022
$SLRX “These initial data explain why we believ... See more
Oct, 28, 2022
$SLRX SP-3164 showed significant tumor growth &q... See more
HEPA
Hepion Pharmaceuticals Inc
-16.85%
$0.86 - $0.72
Feb 7th 2023 - Mar 21st 2023
Mar, 16, 2023
In addition to NASH, Rencofilstat appears to be e... See more
Feb, 17, 2023
but the Liver Cancer (HCC) indication and ability ... See more
TGTX
TG Therapeutics Inc
-19.05%
$18.43 - $14.92
Feb 7th 2023 - Mar 21st 2023
Mar, 21, 2023
$TGTX MOST CONVENIENT- 50% faster infusion SAFE... See more
Mar, 13, 2023
INFUSION TIME 3.NO BREAST CANCER ISSUES 4.
Oct, 28, 2022
$SLRX “These initial data explain why we believe SP-3164 is so exciting, with the potential to make a positive difference in the treatment of hematologic cancers.
Oct, 28, 2022
$SLRX SP-3164 showed significant tumor growth "inhibition" in in vivo studies including statistically significant improvement over the approved immunomodulatory drugs lenalidomide (Revlimid®) and pomalidomide (Pomalyst®)
Mar, 16, 2023
In addition to NASH, Rencofilstat appears to be effective against Multiple Myeloma and Prostate Cancer.
Feb, 17, 2023
but the Liver Cancer (HCC) indication and ability to treat alcohol liver disease alone make Rencofilstat a potential top tier therapeutic - on top of NASH.
Feb, 1, 2023
This makes Rencofilstat a promising candidate for the treatment of a variety of diseases, including thromboembolic disorders, sepsis, and cancer.
Jan, 11, 2023
This cancer stuff is very promising indeed,
Jan, 11, 2023
It is regarded as an incredible drug that almost cures cancer.
Jan, 10, 2023
“killed 70% – 90% of the cancer cells (4 different cell lines) over two days.
Mar, 21, 2023
$TGTX MOST CONVENIENT- 50% faster infusion SAFEST - Zero Breast Cancer Risk MOST AFFORDABLE - By far If TGTX was a Big Pharma Company, the medical press would be blowing it up with praise.
Mar, 13, 2023
INFUSION TIME 3.NO BREAST CANCER ISSUES 4.
Feb, 3, 2023
- Lowest ARR rate, no black box label, reduced brain lesions, and no reports of breast cancer.
Jan, 27, 2023
Lowest ARR rate, no black box warning label, reduced brain lesions, and no reports of breast cancer (there are reports of breast cancer with other MS treatments, and 75% of people with MS are women).
Jan, 16, 2023
$TGTX "4 Stories of Living with Multiple Sclerosis" Briumvi, the best and most affordable, 1HR infusion, no black box label warning, and no warning or report of causing breast cancer.
Jan, 12, 2023
No breast cancer risk.
Jan, 10, 2023
Major upgrade for patients and infusion centers -No major health threats like breast cancer or sever liver damage like main competition
Jan, 6, 2023
$TGTX possibly the best therapy available for MS patients that exists today!
Jan, 5, 2023
MS is 3 times more common in women and there were no reports of breast cancer compared to the competition!